Forward in reverse: How reverse genetics complements chemical genetics

Pharmacogenomics

Volumn 6, Issue 4, 2005, Pages 429-434

  Ross Macdonald, Petra ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Chemical biology; Chemical genetics; Mechanism of action; Molecular libraries initiative; Reverse genetics; RNAi; Small molecule; Target identification

Indexed keywords

FARNESYL TRANS TRANSFERASE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR;

ARTICLE; CHEMICAL GENETICS; DRUG INFORMATION; DRUG RESEARCH; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; GENETIC SCREENING; GENETIC TRANSCRIPTION; GENOTYPE; HIGH THROUGHPUT SCREENING; MEDICAL TECHNOLOGY; PHENOTYPE; RNA INTERFERENCE;

ANIMALS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; GENETICS; HUMANS; PHARMACOGENETICS;

EID: 21444458446     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.6.4.429     Document Type: Article

References (57)

1. Billman GE: RSD-1235 Cardiome. Curr. Opin. Investig. Drugs 4, 352-354 (2003).
2. Clader JW: The discovery of ezetimibe: a view from outside the receptor. J. Med. Chem. 47, 1-9 (2004).
3. Reichert JM: Trends in development and approval times for new therapeutics in the United States. Nature Rev. Drug Discov. 2, 695-702 (2003).
4. Higgs G: DNA 50 years on: has it helped drug discovery? Lancet 361, 1394 (2003).
5. Strausberg RL, Schreiber SL: From knowing to controlling: a path from genomics to drugs using small molecule probes. Science 300, 294-295 (2003).
6. Kelley BP, Lunn MR, Root DE et al.: A flexible data analysis tool for chemical genetic screens. Chem. Biol. 11, 1495-1503 (2004).
7. Root DE, Flaherty SP, Kelley BP, Stockwell BR: Biological mechanism profiling using an annotated compound library. Chem. Biol. 10, 881-892 (2003).
8. Gasparri F, Marani M, Sola F, Galvani A: Quantification of the proliferation index of human dermal fibroblast-cultures with the ArrayScan high-content screening reader. J. Biomol. Screen 9, 232-243 (2004).
9. Stegmaier K, Ross KN, Colavito SA et al.: Gene expression-based high-throughput screening (GE-HTS) and application to leukemia differentiation. Nature Genet. 36, 257-263 (2004).
10. Soppet DR, Castaneda J, Majolagbe A et al.: HITS: a high-throughput integrated transcriptional screen for identifying potential therapeutic agents. Proc. Am. Assoc. Cancer Res. 44, 907 (2003).
11. Giuliano KA, Chen YT, Taylor DL: High-content screening with siRNA optimizes a cell biological approach to drug discovery: defining the role of P53 activation in the cellular response to anticancer drugs. J. Biomol. Screen 9, 557-568 (2004).
12. Perlman ZE, Slack MD, Feng Y et al.: Multidimensional drug profiling by automated microscopy. Science 306, 1194-1198 (2004).
13. Vogt A, Cooley KA, Brisson M et al.: Cell-active dual specificity phosphatase inhibitors identified by high-content screening. Chem. Biol. 10, 733-742 (2003).
14. Schlag BD, Lou Z, Fennell M, Dunlop J: Ligand dependency of 5-hydroxytryptamine 2C receptor internalization. J. Pharmacol. Exp. Ther. 310, 865-870 (2004).
15. Burdine-L, Kodadek T: Target identification in chemical genetics: the (often) missing link. Chem. Biol. 11, 593-597 (2004).
16. Huang J, Zhu H, Haggarty SJ et al.: Finding new components of the target of rapamycin (TOR) signaling network through chemical genetics and proteome chips. Proc. Natl. Acad. Sci. USA 101, 16594-16599 (2004).
17. Searls DB: Data integration - connecting the dots. Nature Biotechnol. 21, 844-845 (2003).
18. Searls DB: Data integration: challenges for drug discovery. Nature Rev. Drug Discov. 4, 45-58 (2005).
19. Giaever G, Chu AM, Ni L et al.: Functional profiling of the Saccharomyces cerevisiae genome. Nature 418, 387-391 (2002).
20. Lum PY, Armour CD, Stepaniants SB et al.: Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes. Cell 116, 121-137 (2004).
21. Giaever G, Flaherty P, Kumm J et al.: Chemogenomic profiling: identifying the functional interactions of small molecules in yeast. Proc. Natl Acad. Sci. USA 101, 793-798 (2004).
22. Tong AH, Lesage G, Bader GD et al.: Global mapping of the yeast genetic interaction network. Science 303, 808-813 (2004).
23. Enyenihi AH, Saunders WS: Large-scale functional genomic analysis of sporulation and meiosis in Saccharomyces cerevisiae. Genetics 163, 47-54 (2003).
24. Hughes TR, Marton MJ, Jones AR et al.: Functional discovery via a compendium of expression profiles. Cell 102, 109-126 (2000).
25. Fire A, Xu S, Montgomery MK et al.: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806-811 (1998).
26. Maeda I, Kohara Y, Yamamoto M, Sugimoto A: Large-scale analysis of gene function in Caenorhabditis elegans by high-throughput RNAi. Curr. Biol. 11, 171-176 (2001).
27. Kamath RS, Martinez-Campos M, Zipperlen P, Fraser AG, Ahringer J: Effectiveness of specific RNA-mediated interference through ingested double-stranded RNA in Caenorhabditis elegans. Genome Biol. 2, 1-10 (2001).
28. Fraser AG, Kamath RS, Zipperlen P et al.: Functional genomic analysis of C. elegans chromosome I by systematic RNA interference. Nature 408, 325-330 (2000).
29. Ashrafi K, Chang FY, Watts JL et al.: Genome-wide RNAi analysis of Caenorhabditis elegans fat regulatory genes. Nature 421, 268-272 (2003).
30. Vastenhouw NL, Fischer SE, Robert VJ et al.: A genome-wide screen identifies 27 genes involved in transposon silencing in C. elegans. Curr. Biol. 13, 1311-1316 (2003).
31. Lee SS, Lee RY, Fraser AG et al.: A systematic RNAi screen identifies a critical role for mitochondria in C. elegans longevity. Nature Genet. 33, 40-48 (2003).
32. Pothof J, van Haaften G, Thijssen K et al.: Identification of genes that protect the C. elegans genome against mutations by genome-wide RNAi. Genes Dev. 17, 443-448 (2003).
33. Lettre G, Kritikou EA, Jaeggi M et al.: Genome-wide RNAi identifies p53-dependent and -independent regulators of germ cell apoptosis in C. elegans. Cell Death Differ. 11, 1198-1203 (2004).
34. McKay RM, McKay JP, Avery L, Graff JM: C. elegans: a model for exploring the genetics of fat storage. Dev. Cell 4, 131-142 (2003).
35. Foley E, O'Farrell PH: Functional dissection of an innate immune response by a genome-wide RNAi screen. PLoS Biol. 2, E203 (2004).
36. Boutros M, Kiger AA, Armknecht S et al.: Genome-wide RNAi analysis of growth and viability in Drosophila cells. Science 303, 832-835 (2004).
37. Echard A, Hickson GR, Foley E, O'Farrell PH: Terminal cytokinesis events uncovered after an RNAi screen. Curr. Biol. 14, 1685-1693 (2004).
38. Wheeler DB, Bailey SN, Guertin DA et al.: RNAi living-cell microarrays for loss-of-function screens in Drosophila Melanogaster cells. Nature Methods 1, 127-132 (2004).
39. Hiesinger PR, Bellen HJ: Flying in the face of total disruption. Nature Genet. 36, 211-212 (2004).
40. Anholt RR, Mackay TF: Quantitative genetic analyses of complex behaviours in Drosophila. Nature Rev. Genet. 5, 838-849 (2004).
41. Heasman J: Morpholino, oligos: making sense of antisense? Dev. Biol 243, 209-214 (2002).
42. Chen E, Ekker SC: Zebrafish as a genomics research model. Curr. Pharm. Biotechnol. 5, 409-413 (2004).
43. Russ A, Dear N, Mudde G et al.: Chemical mutagenesis in the mouse: a powerful tool in drug target identification and validation. In: Model Organisms in Drug Discovery. Carroll PM & Fitzgerald K (Eds), John Wiley and Sons, Chichester, UK, 223-250 (2003).
44. Beltrandelrio H, Kern F, Liggott T et al.: Saturation screening of the druggable mammalian genome. In: Model Organisms in Drug Discovery. Carroll PM & Fitzgerald K (Ed.), John Wiley and Sons, Chichester, UK, 251-278 (2003).
45. Douma S, Van Laar T, Zevenhoven J et al.: Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature 430, 1034-1039 (2004).
46. Huang Q, Raya A, DeJesus P et al.: Identification of p53 regulators by genome-wide functional analysis. Proc. Natl Acad. Sci. USA 101, 3456-3461 (2004).
47. Chanda SK, White S, Orth AP et al.: Genome-scale functional profiling of the mammalian AP-1 signaling pathway. Proc. Natl Acad. Sci. USA 100, 12153-12158 (2003).
48. Kittler R, Putz G, Pelletier L et al.: An endoribonuclease-prepared siRNA screen in human cells identifies genes essential for cell division. Nature 432, 1036-1040 (2004).
49. Berns K, Hijmans EM, Mullenders J et al.: A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 428, 431-437 (2004).
50. Zheng L, Liu J, Batalov S et al.: An approach to genome-wide screens of expressed small interfering RNAs in mammalian cells. Proc Natl. Acad Sci. USA 101, 135-140 (2004).
51. Carroll PM, Fitzgerald K, Kindt R: Mechanism of action in model organisms: interfacing chemistry, genetics and genomics. In: Model Organisms in Drug Discovery. Carroll PM & Fitzgerald K (Ed.), John Wiley and Sons, Chichester, UK, 153-184 (2003).
52. Micchelli CA, Esler WP, Kimberly WT et al.: γ-secretase/presenilin inhibitors for Alzheimer's disease phenocopy Notch mutations in Drosophila. Faseb. J. 17, 79-81 (2003).
53. Smart EJ, De Rose RA, Farber SA: Annexin 2-caveolin 1 complex is a target of ezetimibe and regulates intestinal cholesterol transport. Proc. Natl. Acad. Sci. USA 101, 3450-3455 (2004).
54. Altmann SW, Davis HR Jr, Zhu LJ et al.: Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 303, 1201-1204 (2004).
55. Lackner MR, Kindt RM, Carroll PM et al.: Chemical genetics identifies rab geranylgeranyl transferase as an apoptotic target of farnesyl transferase inhibitors. Cancer Cell 7, 325-326 (2005).
56. Eggert US, Kiger AA, Richter C et al.: Parallel chemical genetic and genome-wide RNAi screens identify cytokinesis inhibitors and targets. PLoS Biol. 2, E379 (2004).
57. Zewail A, Xie MW, Xing Y et al.: Novel functions of the phosphatidylinositol metabolic pathway discovered by a chemical genomics screen with wortmannin. Proc. Natl. Acad. Sci. USA 100, 3345-3350 (2003).